Anthera Pharmaceuticals Inc  

(Public, NASDAQ:ANTH)   Watch this stock  
Find more results for Debra Adams�
2.54
+0.02 (0.79%)
Aug 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.52 - 2.57
52 week 2.39 - 4.26
Open 2.52
Vol / Avg. 46,851.00/142,273.00
Mkt cap 57.69M
P/E     -
Div/yield     -
EPS -3.62
Shares 22.71M
Beta 1.53
Inst. own 56%
Oct 27, 2014
Q3 2014 Anthera Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 28, 2014
Q2 2014 ANTHERA PHARMACEUTICALS INC Earnings Release
Jul 15, 2014
Anthera Pharmaceuticals Inc Acquires Sollpura (liprotamase) from Eli Lilly and Company
Jun 10, 2014
ANTHERA PHARMACEUTICALS INC Annual Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -103.47% -96.65%
Return on average equity -273.40% -549.52%
Employees 25 -
CDP Score - -

Address

Suite B, 25801 Industrial Blvd
HAYWARD, CA 94545
United States - Map
+1-510-8565600 (Phone)
+1-510-8565597 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Anthera Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company�s Phase III candidate, blisibimod, targets B-cell activating factor (BAFF), which has been elevated in a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, (lupus), Immunoglobin A nephropathy (IgA nephropathy), lupus nephritis, vasculitis and others. BAFF, also known as BLyS, is a tumor necrosis family member and is critical to the development, maintenance and survival of multiple B-cell lineages, as well as plasma cells. B-cells and plasma cells are a vital part of the human immune system, producing natural antibody responses to invading pathogens, such as viruses. In July 2014, Anthera Pharmaceuticals Inc acquired Sollpura (liprotamase), a investigational Pancreatic Enzyme Replacement Therapy (PERT) from Eli Lilly and Company.

Officers and directors

Christopher S. Henney Ph.D. Independent Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Paul F. Truex President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
May Liu Senior Vice President - Finance and Administration, Principal Accounting Officer
Age: 38
Bio & Compensation  - Reuters
Debra Odink Ph.D. Senior Vice President, Chief Technology Officer
Age: 50
Bio & Compensation  - Reuters
Paula Adams Ph.D. Senior Vice President - Global Regulatory Affairs and Compliance
Age: 50
Bio & Compensation  - Reuters
Colin Hislop M.D. Senior Vice President, Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Brian R. Mueller Director
Age: 40
Bio & Compensation  - Reuters
Philip T. Sager M.D. Director
Bio & Compensation  - Reuters
Steven B. Engle Independent Director
Age: 59
Bio & Compensation  - Reuters
David E. Thompson Independent Director
Age: 66
Bio & Compensation  - Reuters